HomeFull speed ahead. Keep track of advancements in every frontier

TheTechno Optimist.

BGE-102 (NLRP3)BioAge Labs—BGE-102 (NLRP3)BioAge Labs—BGE-102 (NLRP3)BioAge Labs—BGE-102 (NLRP3)BioAge Labs—BGE-102 (NLRP3)BioAge Labs—BGE-102 (NLRP3)BioAge Labs—

BioAge Labs

Anti-inflammation pill, human aging data

USpublicest. 2015bioagelabs.com (opens bioagelabs.com)Checked 25 Sep

The brief

Analyst view
  • Apr 2026: BGE-102 cut a blood marker of inflammation (hsCRP) by about 85% in people with obesity, with no serious side effects.
  • Its obesity drug trial was stopped in Dec 2024 over liver warning signs, three months after its IPO.
Programs

BioAge Labs, one program

Updated 21 Aug 2026
BGE-102 (NLRP3)A pill that reaches the brain and blocks NLRP3, a switch behind the low-level inflammation that grows with age ('inflammaging').ProtoNextDose-finding trial in heart risk · 2026Updated 21 Aug 2026View program →
Research · Proto · Pilot · Deploy · Scaling

Upcoming catalysts

Company-wide
  • 2027QUELL-DME Phase 1b/2a data in diabetic macular edemaBGE-102 (NLRP3)by ~15 mo

Peers

Anti-aging drugs · 3

Company & funding

HQ
US
Founded
2015

Partners & customers

1 partner

People

Key people
Primer